Developer docs
API playgroundTry for free, no card

Search company profiles

Zelluna Immunotherapy

Full company profile

uuid0004bhw

Namestring
Zelluna Immunotherapy
Legal namestring
Zelluna ASA
Websiteurl
zelluna.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Zelluna Immunotherapy (operating as Zelluna ASA, OSE: ZLNA) is a clinical-stage Norwegian biopharmaceutical company developing allogeneic, off-the-shelf T Cell Receptor-Natural Killer (TCR-NK) cell therapies for solid tumours. Founded in 2016 and headquartered at the Oslo Cancer Cluster Innovation Park, the company became publicly listed on the Oslo Stock Exchange in March 2025 following a business combination with Ultimovacs ASA. Its core proprietary platform combines the precise antigen targeting of engineered T cell receptors with the innate cytotoxic activity of natural killer cells, designed to address tumour heterogeneity, antigen loss, and scalability constraints that have limited autologous cell therapies in solid cancers.

The company's lead product candidate, ZI-MA4-1, is the world's first MAGE-A4-targeting TCR-NK therapy and is currently being evaluated in the ZIMA-101 first-in-human Phase 1 clinical trial following UK MHRA approval in February 2026, with first site activation at The Christie NHS Foundation Trust in May 2026. Pipeline expansion includes a KKLC1-targeting TCR program developed in collaboration with Etcembly using its AI-enabled EMLy platform. Zelluna holds a landmark granted patent providing broad protection over the TCR-NK field and has developed a proprietary manufacturing process capable of producing hundreds of doses per GMP batch. The company employs between 11 and 50 people and engages Medpace as clinical CRO.

Zelluna is pre-revenue, with FY2025 operating expenses of NOK 143.8 million and a Q1 2026 loss of NOK 20.4 million. The business model contemplates eventual commercialization through oncology hospital contracts or pharmaceutical partnerships following regulatory approval, generating revenue from one-time cell therapy product sales; no commercial pricing has been disclosed. Capital is raised through equity issuances on the Oslo market, with two private placements in November 2025 (NOK 58 million) and June 2026 (NOK 58.2 million) supporting clinical execution, with cash runway extended into Q1 2027.

Short descriptiontext

Zelluna Immunotherapy is a publicly listed Norwegian biotech developing allogeneic TCR-NK cell therapies for solid tumours, with lead candidate ZI-MA4-1 in a UK Phase 1 trial and a KKLC1 pipeline program built via AI-enabled TCR engineering.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOslo, Norway
HQ citystring
Oslo
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy platform, TCR-NK immunotherapy, allogeneic cell therapy, solid tumor therapy, cancer immunotherapy
Industry3 codes
PRIMARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Cell Therapy
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Cell Therapy Product Sales
TypeOne Time License
Description

Pre-revenue biopharmaceutical company developing allogeneic TCR-NK cell therapies for cancer treatment. Expected to generate revenue through product sales following regulatory approval and commercialization.

zelluna.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Zelluna Immunotherapy develops an allogeneic, off-the-shelf T Cell Receptor-based Natural Killer (TCR-NK) cell therapy platform for the treatment of solid cancers. Its lead product candidate, ZI-MA4-1, is the world's first MAGE-A4-targeting TCR-NK therapy currently in Phase 1 clinical trials (ZIMA-101 study). The pipeline includes a KKLC1-targeting TCR-NK program developed in collaboration with Etcembly using AI-enabled TCR engineering.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • First GMP batch successfully manufactured December 2025 for first-in-human trial
+1 more record
Product overview1 text field

Zelluna Immunotherapy is a Norwegian biotech company pioneering an allogeneic 'off-the-shelf' TCR-NK cell therapy platform for solid cancers. The company's core platform combines T cell receptor (TCR) targeting with natural killer (NK) cell cytotoxicity. The lead product, ZI-MA4-1, is the world's first MAGE-A4-targeting TCR-NK therapy currently in Phase 1 clinical trials (ZIMA-101 study). The pipeline includes a KKLC1-targeting program developed through AI-enabled collaboration with Etcembly. The platform is designed to overcome key challenges in solid tumour treatment including tumour heterogeneity and antigen loss, while offering scalable manufacturing and broad patient access.

Product and service3 records
1ZI-MA4-1
CategoryCore Cell Therapy Product
Description

World's first MAGE-A4-targeting off-the-shelf allogeneic TCR-NK cell therapy candidate for treatment of solid cancers including lung, ovarian, head and neck cancers, and sarcomas. Combines precise T cell receptor targeting with innate NK cell cytotoxicity.

2TCR-NK Platform
CategoryTherapeutic Platform
Description

Proprietary allogeneic off-the-shelf T Cell Receptor-based Natural Killer cell therapy platform combining precise solid tumour targeting of TCRs with the potent, broad cancer-killing ability of NK cells. Designed to overcome limitations of current cell therapies in solid tumours and enable scalable, cost-effective production.

3KKLC1 TCR-NK Program
CategoryPipeline Program
Description

Pipeline expansion program engineering TCRs targeting the KKLC1 cancer antigen for use within the TCR-NK platform. Expands the company's target portfolio beyond MAGE-A4 to address a broader spectrum of solid cancers. Developed in collaboration with Etcembly using AI-enabled engineering via the EMLy platform.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-09
Description

Collaboration leveraging Etcembly's AI platform EMLy to engineer high-affinity TCRs targeting KKLC1 cancer antigen for use in allogeneic TCR-NK cell therapy platform. Builds on successful previous collaboration that produced ZI-MA4-1. In-vitro data expected Q4 2026.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-02-11
Description

Global contract research organization selected to support first-in-human Phase 1 clinical trial of ZI-MA4-1. Medpace provides clinical operations, trial management, regulatory support, data management, and pharmacovigilance services.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zelluna Immunotherapy

Cancer Cell Therapyzelluna.com

Zelluna Immunotherapy is a publicly listed Norwegian biotech developing allogeneic TCR-NK cell therapies for solid tumours, with lead candidate ZI-MA4-1 in a UK Phase 1 trial and a KKLC1 pipeline program built via AI-enabled TCR engineering.

What Zelluna Immunotherapy does

Zelluna Immunotherapy (operating as Zelluna ASA, OSE: ZLNA) is a clinical-stage Norwegian biopharmaceutical company developing allogeneic, off-the-shelf T Cell Receptor-Natural Killer (TCR-NK) cell therapies for solid tumours. Founded in 2016 and headquartered at the Oslo Cancer Cluster Innovation Park, the company became publicly listed on the Oslo Stock Exchange in March 2025 following a business combination with Ultimovacs ASA. Its core proprietary platform combines the precise antigen targeting of engineered T cell receptors with the innate cytotoxic activity of natural killer cells, designed to address tumour heterogeneity, antigen loss, and scalability constraints that have limited autologous cell therapies in solid cancers.

The company's lead product candidate, ZI-MA4-1, is the world's first MAGE-A4-targeting TCR-NK therapy and is currently being evaluated in the ZIMA-101 first-in-human Phase 1 clinical trial following UK MHRA approval in February 2026, with first site activation at The Christie NHS Foundation Trust in May 2026. Pipeline expansion includes a KKLC1-targeting TCR program developed in collaboration with Etcembly using its AI-enabled EMLy platform. Zelluna holds a landmark granted patent providing broad protection over the TCR-NK field and has developed a proprietary manufacturing process capable of producing hundreds of doses per GMP batch. The company employs between 11 and 50 people and engages Medpace as clinical CRO.

Zelluna is pre-revenue, with FY2025 operating expenses of NOK 143.8 million and a Q1 2026 loss of NOK 20.4 million. The business model contemplates eventual commercialization through oncology hospital contracts or pharmaceutical partnerships following regulatory approval, generating revenue from one-time cell therapy product sales; no commercial pricing has been disclosed. Capital is raised through equity issuances on the Oslo market, with two private placements in November 2025 (NOK 58 million) and June 2026 (NOK 58.2 million) supporting clinical execution, with cash runway extended into Q1 2027.

Zelluna Immunotherapy firmographics

Firmographics
Name
Zelluna Immunotherapy
Legal name
Zelluna ASA
Website
https://zelluna.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Zelluna Immunotherapy is a publicly listed Norwegian biotech developing allogeneic TCR-NK cell therapies for solid tumours, with lead candidate ZI-MA4-1 in a UK Phase 1 trial and a KKLC1 pipeline program built via AI-enabled TCR engineering.
Ownership category
akta.pro rank

Zelluna Immunotherapy industry classification

Industry
Product category
Cancer Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell therapy platform
  • TCR-NK immunotherapy
  • Allogeneic cell therapy
  • Solid tumor therapy
  • Cancer immunotherapy

Where Zelluna Immunotherapy is headquartered

Location

Headquarters

HQ city
Oslo
HQ country
Norway
HQ region
Europe

Offices1 record

Markets served

Zelluna Immunotherapy business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Cell Therapy Product Sales: Pre-revenue biopharmaceutical company developing allogeneic TCR-NK cell therapies for cancer treatment. Expected to generate revenue through product sales following regulatory approval and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Zelluna Immunotherapy product offering

Product offering

Core offering

Zelluna Immunotherapy develops an allogeneic, off-the-shelf T Cell Receptor-based Natural Killer (TCR-NK) cell therapy platform for the treatment of solid cancers. Its lead product candidate, ZI-MA4-1, is the world's first MAGE-A4-targeting TCR-NK therapy currently in Phase 1 clinical trials (ZIMA-101 study). The pipeline includes a KKLC1-targeting TCR-NK program developed in collaboration with Etcembly using AI-enabled TCR engineering.

Product overview

Zelluna Immunotherapy is a Norwegian biotech company pioneering an allogeneic 'off-the-shelf' TCR-NK cell therapy platform for solid cancers. The company's core platform combines T cell receptor (TCR) targeting with natural killer (NK) cell cytotoxicity. The lead product, ZI-MA4-1, is the world's first MAGE-A4-targeting TCR-NK therapy currently in Phase 1 clinical trials (ZIMA-101 study). The pipeline includes a KKLC1-targeting program developed through AI-enabled collaboration with Etcembly. The platform is designed to overcome key challenges in solid tumour treatment including tumour heterogeneity and antigen loss, while offering scalable manufacturing and broad patient access.

Differentiator

Problem solved

Functional benefit

Products and services

  • ZI-MA4-1 World's first MAGE-A4-targeting off-the-shelf allogeneic TCR-NK cell therapy candidate for treatment of solid cancers including lung, ovarian, head and neck cancers, and sarcomas. Combines precise T cell receptor targeting with innate NK cell cytotoxicity.
  • TCR-NK Platform Proprietary allogeneic off-the-shelf T Cell Receptor-based Natural Killer cell therapy platform combining precise solid tumour targeting of TCRs with the potent, broad cancer-killing ability of NK cells. Designed to overcome limitations of current cell therapies in solid tumours and enable scalable, cost-effective production.
  • KKLC1 TCR-NK Program Pipeline expansion program engineering TCRs targeting the KKLC1 cancer antigen for use within the TCR-NK platform. Expands the company's target portfolio beyond MAGE-A4 to address a broader spectrum of solid cancers. Developed in collaboration with Etcembly using AI-enabled engineering via the EMLy platform.

Quantifiable outcome

  • First GMP batch successfully manufactured December 2025 for first-in-human trial
  • +1 more outcomes

Companies that use Zelluna Immunotherapy

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Zelluna Immunotherapy technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Zelluna Immunotherapy partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Etcembly LtdcoreStrategic or Co-development Partner · 9 March 2026Collaboration leveraging Etcembly's AI platform EMLy to engineer high-affinity TCRs targeting KKLC1 cancer antigen for use in allogeneic TCR-NK cell therapy platform. Builds on successful previous collaboration that produced ZI-MA4-1. In-vitro data expected Q4 2026.
  • MedpacecoreImplementation/ SI/ Consulting Partner · 11 February 2026Global contract research organization selected to support first-in-human Phase 1 clinical trial of ZI-MA4-1. Medpace provides clinical operations, trial management, regulatory support, data management, and pharmacovigilance services.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Zelluna Immunotherapy competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Zelluna Immunotherapy financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zelluna Immunotherapy leadership team

Management profile

Number of profiles

Profiles8 records

Zelluna Immunotherapy funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zelluna Immunotherapy M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zelluna Immunotherapy

What does Zelluna Immunotherapy do?

Zelluna Immunotherapy develops an allogeneic, off-the-shelf T Cell Receptor-based Natural Killer (TCR-NK) cell therapy platform for the treatment of solid cancers. Its lead product candidate, ZI-MA4-1, is the world's first MAGE-A4-targeting TCR-NK therapy currently in Phase 1 clinical trials (ZIMA-101 study). The pipeline includes a KKLC1-targeting TCR-NK program developed in collaboration with Etcembly using AI-enabled TCR engineering.

Is Zelluna Immunotherapy a public or private company?

Zelluna Immunotherapy is a public company. It is classified as public and is currently operating.

When was Zelluna Immunotherapy founded?

Zelluna Immunotherapy was founded in 2016. It employs 11 to 50 people.

Where is Zelluna Immunotherapy based?

Zelluna Immunotherapy is headquartered in Oslo, Norway, in the Europe region.

How does Zelluna Immunotherapy make money?

One revenue line is on record: cell Therapy Product Sales.

Does Zelluna Immunotherapy have an API?

No public API is recorded for Zelluna Immunotherapy.

What industry is Zelluna Immunotherapy in?

Zelluna Immunotherapy's product category is Cancer Cell Therapy. Its primary akta.pro industry code is HLAAABAD, NK Cell Therapies, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewZelluna on its clinical momentum as TCR-NK trial advances towards dose escalationZelluna initiated its first-in-human ZIMA-101 trial, with two patients treated and recruitment on track. No dose-limiting toxicities have been reported, and the company aims to complete the first dose cohort and progress to higher doses in 2027.TradingViewZLNA: Early clinical progress and favorable safety; cohort 2 expected by early Q2 2027Zelluna ASA reported that two patients received dose-level-1 treatment with no dose-limiting toxicities, while imaging and efficacy assessments remain ongoing. The company held NOK 60m in cash at Q3-end, and cohort 2 is expected by early Q2 2027.Business & FinancialZelluna ASA: Third Quarter 2026 ResultsZelluna reported Q3 2026 results, with two patients dosed in its ZIMA-101 study and no dose-limiting toxicities. The company expects to complete Dose Level 1 and begin Dose Level 2 in Q1-Q2 2027. It also received a NOK 15.6 million grant from the Research Council of Norway.TradingViewZelluna ASA awarded NOK 15.6 million Research Council of Norway grant to further advance TCR-NK manufacturingZelluna ASA received a NOK 15.6 million grant from the Research Council of Norway to advance manufacturing of its allogeneic TCR-NK cell therapies. The funding aims to increase patient doses per donor and reduce cost of goods, supporting broader access to solid cancer treatments.TradingViewZelluna ASA (ZLNA) Wins NOK 15.6M Manufacturing GrantZelluna ASA received a NOK 15.6M grant from the Research Council of Norway to improve TCR-NK manufacturing. The project aims to increase doses per donor and reduce cost per dose, with no prior-period comparison provided.GlobeNewswireZelluna ASA tildelt NOK 15,6 millioner fra Norges forskningsråd for videre utvikling av selskapets TCR-NK-produksjonZelluna received a NOK 15.6 million grant from Norges forskningsråd to develop its TCR-NK cell therapy production process. The funds aim to lower production costs and increase doses per donor, supporting broader access for solid tumor patients. Final contract terms are still pending.GlobeNewswireZelluna ASA awarded NOK 15.6 million Research Council of Norway grant to further advance TCR-NK manufacturingZelluna ASA received a NOK 15.6 million grant from the Research Council of Norway to advance manufacturing of its TCR-NK cell therapies. The funding aims to increase patient doses per donor and reduce cost of goods, supporting broader access to solid cancer treatments.GlobeNewswireZelluna ASA: Invitation to Third Quarter 2026 Results Webcast Including ZIMA-101 Clinical Progress UpdateZelluna will publish its Q3 2026 financial results and a webcast on 5 November 2026, including an update on the Phase 1 ZIMA-101 study of ZI-MA4-1. The presentation will be available via live webcast at 09:00 CET, with materials published at 07:00 CET.Investing.comZelluna reports Q2 loss as cancer therapy trial advances By Investing.comNorwegian cell therapy company Zelluna reported an operating loss of NOK 19.7 million for the second quarter while advancing its cancer treatment trial by dosing its first patient in the Phase 1 study of ZIMA-101. The company raised NOK 58.2 million through a private placement and retail offering, supplemented by a NOK 16 million grant, to support ongoing operations and clinical activities. Zelluna stated that its current cash position will fund operations into the third quarter of 2027 as it continues patient recruitment at two clinical sites.AInvestZelluna ASA - cash position is expected to fund planned operations into Q3 of 2027Zelluna ASA reported a cash position of MNOK 49.3 as of March 2026, extending its financial runway to fund operations into Q3 2027. The company activated its first clinical site for the ZIMA-101 study and received CTA approval for lead candidate ZI-MA4-1 during the quarter. This extended runway reduces the immediate need for additional capital raising while the company advances its TCR-NK platform.